Glycated apolipoprotein B (Gly-ApoB)

Glycated apolipoprotein B (Gly-ApoB) is a post-translationally modified form of apolipoprotein B-100, the primary structural protein found in low-density lipoproteins (LDL) and other atherogenic lipoprotein particles [5, 11]. This modification occurs via the non-enzymatic attachment of glucose to lysine and arginine residues, a process that is significantly accelerated under conditions of chronic hyperglycemia, such as in diabetes mellitus [5, 6]. Glycation of these critical residues disrupts the ability of LDL particles to be recognized and cleared by the hepatic LDL receptor, resulting in an extended plasma half-life and elevated levels of circulating modified lipids [1, 5]. These modified particles are highly susceptible to arterial wall entrapment and are preferentially recognized by scavenger receptors on macrophages, leading to the formation of foam cells and the progression of atherosclerotic plaques [3, 9]. Beyond its role as a modified lipid transporter, Gly-ApoB serves as a pro-inflammatory stimulus by activating signaling pathways such as the Toll-like receptor 4 (TLR4) and the receptor for advanced glycation end-products (RAGE) [9, 13]. These interactions trigger the production of reactive oxygen species and inflammatory cytokines, contributing to endothelial dysfunction and vascular calcification [11, 13]. Therapeutic strategies currently focus on reducing Gly-ApoB formation through strict glycemic control and the use of lipid-lowering agents like statins, which have been shown to reduce levels of both glycated and oxidized LDL in diabetic patients [11, 12]. Emerging research also explores the use of glycomimetics and specific glycation-site blockers to directly prevent the pathogenic effects of this modified protein in cardiovascular disease [4, 13].

Other names

Glycosylated apolipoprotein BGly-ApoB-100Amadori-modified apolipoprotein BGlycated low-density lipoprotein apolipoprotein BAdvanced glycation end-product modified apolipoprotein B

Reduction of glycated apolipoprotein levels through intensive lipid-lowering therapy, inhibition of non-enzymatic glycation reactions, or the blockade of downstream signaling pathways mediated by receptors such as RAGE and TLR4.